Prof. Farhad Hafezi from the ELZA Institute provided an insightful update on the Second Global Consensus on Keratoconus during an interview with EyeTube.
Prof. Hafezi presents Femto-CAIRS and high fluence cross-linking, highlighting its advantages for keratoconus treatment and improving visual outcomes
Recent corneal cross-linking advances extend beyond disease stabilization, introducing individualized and second-generation customized treatment approaches for keratoconus.
The AAO-ESCRS Joint Symposium, convened leading ophthalmology experts to explore the latest developments in CXL.
The STEP system utilizes two parameters: the minimum overall stromal thickness (ST) and the standard deviation of epithelial thickness (EP). This approach provides a more detailed understanding of keratoconus progression, offering insights that may assist in clinical decisions, especially concerning corneal cross-linking (CXL) protocols.
ELZA-PACE not only improves corneal biomechanics (just like regular CXL) but by flattening the cone significantly, also enhances patients’ visual quality. The results so far indicate that patients treated with this method have better visual outcomes compared to traditional CXL treatments.
On August 12, 2023, at Humo Arena, Tashkent, 63 Down syndrome children were screened for keratoconus under Nikki Hafezi’s leadership. Discover the importance of early detection.
Ophthalmologie Nachrichten recently featured an article from the ELZA Institute, highlighting advancements in corneal cross-linking (CXL). This new approach allows the procedure to be conducted at the slit lamp, significantly reducing costs and extending access to advanced eye care in underserved regions. The innovative method is especially effective for treating keratoconus and infectious keratitis. By optimizing UV exposure times, ELZA’s researchers have made CXL more efficient and accessible, democratizing high-quality ophthalmic treatments globally.
Nikki Hafezi, a partner of MESCA Foundation, is leading healthcare transformation in Uzbekistan. MESCA, founded in 2021 by Bakhtiyor Fazylov, focuses on medical education, training, and research. It aims to enhance ophthalmological care, particularly addressing keratoconus, a significant cause of preventable blindness in children. MESCA’s initiatives include training local healthcare professionals and collaborating with institutions like the Andijan State Medical Institute to improve medical practice and education.
Discover the latest advancements in keratoconus treatment with the ELZA Institute’s innovative techniques: transPRK, PACE, and All Femto-CAIRS, as featured in The Ophthalmologist.
